1. Show article details.

    VIVUS Reports Fourth Quarter and Year-End 2014 Financial Results

    Market Wire – 4:00 PM ET 02/24/2015

    02/24/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today provided a business update and reported its financial results for the fourth quarter and year ended December 31, 2014.

  2. Show article details.

    VIVUS to Present at Upcoming Investor Conference

    Market Wire – 7:00 AM ET 02/20/2015

    02/20/15 -- VIVUS, Inc. (VVUS) today announced that management will present an overview of the company at the following investment conference: 2015 RBC Capital Markets' Global Healthcare Conference February 25, 2015, 3:35pm EST New York Palace Hotel, New York, NY. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

  3. Show article details.

    VIVUS Announces Date of Fourth Quarter and Year End 2014 Update and Financial Results Conference Call

    GlobeNewswire – 7:00 AM ET 02/19/2015

    VIVUS, Inc. (VVUS) today announced that it will report financial results for the fourth quarter and year ended December 31, 2014 after the NASDAQ Market closes on Tuesday, February 24, 2015. Date: February 24, 2015 Time: 4:30 PM EST. Listen via Internet: http://ir.vivus.com/ Schedule this webcast into MS-Outlook calendar: http://apps.shareholder.com/PNWOutlook/t.aspx?m=67953&k=64288A08.

  4. Show article details.

    VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity

    Market Wire – 7:00 AM ET 01/29/2015

    01/29/15 -- VIVUS, Inc. (VVUS) today announced that the European Commission has adopted the commission implementing decision amending the marketing authorization for SPEDRA. "We are pleased with the EC decision to approve the label amendment for SPEDRA," said Seth H. Z. Fischer, Chief Executive Officer of VIVUS.

  5. Show article details.

    Vivus Inc. Faces Strong Growth in 2015, Narrowing Loss Estimates and Large Stakes of Vivus Being Purchased by North Tide Capital: Analyst Report Issued By BrokerBank Securities, Inc.

    PR Newswire – 7:00 AM ET 01/15/2015

    NEW YORK, Jan. 15, 2015 Vivus Inc. (VVUS) is based out of Mountain View, California and is a biopharmaceutical company. The company is expected to present an overview of their current position at the 33rd annual J.P. Morgan Healthcare Conference on January 15th, 2015, 9:00am PST.

  6. Show article details.

    Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom

    PR Newswire – 8:35 AM ET 01/12/2015

    LONDON, January 12, 2015 Investor-Edge has initiated coverage on the following equities: Johnson and Johnson (JNJ), VIVUS Inc. (VVUS), Actavis PLC (ACT), Covance Inc. (CVD), and Sequenom Inc. (SQNM). Free research on these five companies can be accessed at: http://investor-edge.com/register.

  7. Show article details.

    VIVUS to Present at Upcoming Investor Conference

    Market Wire – 7:00 AM ET 01/09/2015

    01/09/15 -- VIVUS, Inc. (VVUS) today announced that management will present an overview of the company at the following investment conference: 33rd Annual J.P. Morgan Healthcare Conference January 15, 2015, 9:00am PST Westin St. Francis Hotel, San Francisco, California A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

  8. Show article details.

    VIVUS Announces Favorable Formulary Positioning for Qsymia

    Market Wire – 7:00 AM ET 12/15/2014

    12/15/14 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing Qsymia® capsules CIV for the treatment of obesity, today announced that Qsymia is the sole anti-obesity agent listed on the CVS/Caremark Performance Drug List, or PDL. "We are pleased that Qsymia is recognized as the preferred anti-obesity therapy on the CVS/Caremark PDL," said Seth H. Z. Fischer, CEO.

  9. Show article details.

    VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia

    Market Wire – 7:00 AM ET 11/26/2014

    11/26/14 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing Qsymia® capsules CIV for the treatment of obesity, today announced that the United States Patent and Trademark Office has issued U.S. Patent Nos. "Our efforts continue toward enhancing the value of the Qsymia patent portfolio," said Seth H. Z. Fischer, CEO.

  10. Show article details.

    VIVUS Reports Third Quarter 2014 Financial Results

    Market Wire – 4:00 PM ET 11/05/2014

    11/05/14 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing Qsymia® capsules CIV for the treatment of obesity, today reported its financial results for the third quarter ended September 30, 2014 and provided a business update.

  11. Show article details.

    VIVUS Announces Qsymia Presentations at Obesity Week 2014

    Market Wire – 7:00 AM ET 11/03/2014

    11/03/14 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing Qsymia® capsules CIV for the treatment of obesity, today announced the following presentations at Obesity Week 2014, Boston Convention and Exhibit Center.

  12. Show article details.

    VIVUS Announces Date of Third Quarter 2014 Update and Financial Results Conference Call

    GlobeNewswire – 7:00 AM ET 10/30/2014

    VIVUS, Inc. (VVUS) today announced that it will report financial results for the third quarter ended September 30, 2014 after the NASDAQ Market closes on Wednesday, November 5, 2014. Date: November 5, 2014 Time: 4:30 PM ET. Listen via Internet: http://ir.vivus.com/ Schedule this webcast into MS-Outlook calendar: http://apps.shareholder.com/PNWOutlook/t.aspx?m=66840&k=43CB670F.

  13. Show article details.

    Newly Published Data Highlight the Effects of Weight Loss With Qsymia in Type 2 Diabetes

    Market Wire – 7:00 AM ET 10/06/2014

    10/06/14 -- VIVUS, Inc. (VVUS) today announced the publication of a paper examining study results that demonstrate the positive impact of weight loss with Qsymia® capsules CIV plus lifestyle modification on glycemic control in subjects with type 2 diabetes. The paper was published online in the journal Diabetes Care.

  14. Show article details.

    VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity

    Market Wire – 6:00 AM ET 09/18/2014

    09/18/14 --  VIVUS, Inc. (VVUS) and Auxilium Pharmaceuticals (AUXL), Inc. today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for STENDRA®. STENDRA is now the only FDA-approved erectile dysfunction medication indicated to be taken as early as approximately 15 minutes before sexual activity.

Page:

Today's and Upcoming Events

  • May
    5

    VVUS to announce Q1 earnings After Market (Unconfirmed)

Past Events (last 90 days)

  • Feb
    24

    VVUS Earnings Conference Call at 4:30 PM Listen

  • Feb
    24

    VVUS to announce Q4 earnings

    • Next earnings date: 5/5/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.